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Abstract
Protein aggregates are a major risk factor for immunogenicity. Until now most studies on aggregate-driven immunogenicity
have focused on linking physicochemical features of the aggregates to the formation of anti-drug antibodies. Lacking is
however, basic knowledge on the effect of aggregation on the biodistribution and clearance of therapeutic proteins in vivo.
The aim of current study was to get insight into the effect of aggregation on biodistribution in mice using different routes of
administration. Fluorescently labeled stressed and unstressed mouse serum albumin was injected via different routes in
mice and detected via in vivo fluorescence imaging up to 48 hrs post-injection. We found that biodistribution of stressed
MSA significantly differed from its unstressed counterpart. Subcutaneous and intramuscular administration resulted in
accumulation of protein at the site of injection, from which clearance of stressed MSA was considerably slower than
clearance of unstressed MSA. Upon intravenous and intraperitoneal injection of stressed MSA, fluorescent ‘‘hotspots’’ were
observed in the spleens, livers and lungs. Further and more detailed examination of biodistribution after intraperitoneal
injection showed higher fluorescence in most of tested organs suggesting more efficient diffusion and/or lymphatic uptake
from peritoneum of unstressed MSA than the stressed formulation.
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Introduction
Therapeutic proteins have revolutionized the therapy of many
diseases like multiple sclerosis, rheumatoid arthritis, Crohn’s
disease and many others. Unfortunately, therapeutic proteins are
immunogenic and cause the production of anti-drug antibodies
(ADA) in some patients. These ADA can decrease the treatment
efficiency and can lead to severe side effects [1–3].
Among many risk factors that could induce the production of
ADA protein aggregates seem to be critical. An increasing number
of reports link the presence of protein aggregates in the formulated
product to an increased risk of ADA formation [4–9]. Various
physicochemical features including aggregate size, molecular
weight , composition and rigidity have been studied to determine,
which are critical in immunogenicity [6–8]. However, data on
aggregates’ fate after their administration into patients is very
limited. Filipe et al. showed that incubation of human monoclonal
IgG aggregates in plasma for 24 hrs resulted in alteration of the
total number of aggregates, led to different aggregate size and
changed their structure [10]. These results indicate that aggregates
can undergo significant modifications after coming in contact with
biological fluids.
Many reports, both from clinical and animals studies, have
shown that the route of injection might have a significant impact
on immunogenicity of therapeutic proteins [11–14]. One of the
explanations of this phenomenon is distinct biodistribution of
drugs after administration via different routes [15,16]. However,
studies comparing biodistribution of (aggregated) proteins admin-
istered via different routes are lacking. Since the physicochemical
characteristics of aggregates and monomers differ significantly, it
seems likely that the biodistribution of these species is also
different. In fact, existing literature seems to suggest differences in
biodistribution of protein monomers and aggregates. For example,
it has been shown that uptake of proteins after subcutaneous (SC)
injection occurs mainly via lymphatic transportation, which can
carry macromolecules and particulates up to 100 nm in diameter
[17]. However, as aggregates often exceed this size, one could
imagine that clearance of aggregates from the injection site upon
SC administration will be slower than that of monomers.
Decomposition of protein aggregates might be necessary prior to
their removal. One could also hypothesize that after intravenous
(IV) injection protein aggregates are cleared from circulation by
the reticuloendothelial system as it has been shown for liposomes
[18]. However, these hypotheses need to be confirmed.
This report describes a series of experiments designed to study
the biodistribution of aggregated proteins after administration in a
mouse model. In order to obtain an autologous system mimicking
human situation we used mouse serum albumin (MSA) as a model
protein, which was labeled with an infrared fluorescence probe to
allow detection in vivo and ex-vivo. In the first experiment we
administered unstressed or stressed (aggregated) MSA via four
different injection routes: intraperitoneal (IP), IV, SC or
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intramuscular (IM) and assessed fluorescence over a period of
48 hours. In a follow up study we determined in more detail the
biodistribution of unstressed and stressed MSA over time after IP
injection.
Materials and Methods
1. Animals
All testing was performed according to the EU Directives 86/
609/EEC and 2010/63/EU. The work protocols have been
approved by Utrecht Animal Experiments Committee (DierEx-
perimentenCommissie Utrecht, permission numbers: DEC
no. 2012.II.04.064 and 2012.II.07.099). All procedures were kept
to minimum to limit animals’ discomfort. Animals were sacrificed
by decapitation preceded by isoflurane anesthesia.
FvB/N females (5–6 weeks old) were purchased from Charles
River (The Netherlands). Animals were housed in standard
perspex cages with free access to food and water (acidified). To
reduce food-induced fluorescence in the intestinal track, animals
received chlorophyll free diet (Harlan Laboratories, The Nether-
lands). In order to eliminate autofluorescence caused by the fur,
mice were completely shaven and treated with Veet cream (local
pharmacy) to remove remaining hair.
2. Protein labeling and stressing
MSA (Sigma Aldrich, the Netherlands) was reconstituted in
phosphate buffered saline (PBS) to a concentration of 5 mg/ml. It
was labeled with Alexa Fluor 700 carboxylic acid succinimidyl
ester (Invitrogen, the Netherlands) according to the manufacturer
protocol. The molar ratio of dye to protein was 10:1. After
labeling, the free dye was removed by overnight dialysis against
PBS. The degree of protein labeling was determined according to
the manufacturer’s protocol and was equal to 3 Alexa700 dye
molecules per one MSA molecule.
Stressed MSA-Alexa700 was acquired via metal catalyzed
oxidation. First, MSA-Alexa700 conjugates were dialyzed over-
night (O/N) against 50 mM HEPES, 100 mM KCl, 10 mM
MgCl2, pH 7.4 (oxidation buffer). After dialysis MSA was diluted
to a concentration of ,1.2 mg/ml and the oxidation procedure
was initiated by adding FeCl3 and ascorbic acid to final
concentrations of 100 mM and 2.5 mM, respectively. The
solution was kept at 37uC for one hour, after which the oxidation
reaction was terminated by the addition of EDTA to a final
concentration of 1 mM. Afterwards, stressed MSA-Alexa700 was
again O/N dialyzed against PBS. Protein concentration was
determined by a MicroBCAH assay according to the manufactur-
er’s protocol (Thermo Fisher Scientific, The Netherlands). MSA-
Alexa700 solutions (stressed and unstressed) were diluted to a final
concentration of 1 mg/ml, aliquoted and stored at 4uC (short term
storage, ,week) or 220uC (long term storage, up to 4 weeks).
3. Characterization of unstressed and stressed MSA
Visual inspection. Stressed samples were visually inspected
to determine the presence of visible particles. Unstressed MSA-
Alexa700 formulation was used as a reference.
Size-Exclusion Chromatography (SEC). SEC was per-
formed on a Waters 2699 Aliance (Waters, USA) equipped with
a WATERS 2487 Dual l absorbance detector and a WATERS
2475 Multi l fluorescence detector. Proteins were separated on a
Superdex 200 column (GE Health Care Life Sciences, Belgium).
The elution buffer was composed of 50 mM phosphate buffer,
200 mM NaCl and pH 7.4. Before analysis both the buffer and
the MSA-Alexa700 samples were filtered through a 0.45 mm
Nylon filter. A volume of 100 ml stressed or unstressed MSA-
Alexa700 solution was applied to the column and the separation
was performed with a flow rate of 0.5 ml/min. UV detection was
performed at a wavelength of 280 nm (A280) and fluorescence was
induced at 702 nm and detected at 720 nm (F720).
In order to calculate the amount of free dye in the formulations
the area under the curve (AUC) was calculated for the F720 signal.
The percentage of oligomers, monomers and fragments of MSA
present in both stressed and unstressed formulations were
calculated for the AUC measured at A280. To calculate the
recovery of the stressed MSA-Alexa700 after filtration, the AUC of
stressed MSA-Alexa700 was compared with the AUC of the
unstressed MSA-Alexa700, which was referred to as 100%.
Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS-PAGE). The SDS-PAGE analysis was
performed with the X-Cell Sure Lock@ Mini-Cell system
(Invitrogen, the Netherlands). 0.5 mg or 1 mg of stressed and
unstressed MSA-Alexa700 were loaded on the NuPAGEH 4–12%
Bis-Tris Mini Gels of 1 mm thickness (NovexH, Invitrogen, the
Netherlands). Protein samples were separated under non-reducing
conditions at 130 V for 60 minutes. Proteins were visualized by
silver staining and by detection of fluorescence using the infra-red
imager Odyssey (LiCore, Germany).
Dynamic Light Scattering (DLS) and NanoParticle
Tracking Analysis (NTA). DLS measurements were per-
formed on a Malvern ALV CGS-3 goniometer (Malvern
Instruments, Malvern, UK) coupled to an LSE-5003 autocorre-
lator and a He\Ne laser (25 mW, output power, l=632.8 nm).
Data were obtained at 25uC and the laser was operating at an 90u
angle. Data were captured by the ALV correlator software
(Malvern, UK) and analyzed using the DTS (Nano) software
(Malvern, UK).
In addition, both stressed and unstressed MSA-Alexa700 were
analyzed for the number of particles using the NanoSize LM14
(NanoSight Ltd., UK) equipped with an EMCCD/Andor camera
and a 532 nm laser. Particle count and size distribution were
analyzed by three 60 s measurements.
2. In vivo studies
Experiment 1: Biodistribution of unstressed and stressed
MSA upon injection via different routes. A volume of 50 ml
(50 mg) of unstressed or stressed MSA-Alexa700 was injected via
one of following routes: IP, IV, IM (right hind leg) or SC (neck),
(n = 5). Fluorescence was measured by the BioSpace Photon
ImagerTM (Biospace Lab, France) before injection, directly post
injection (p.i.), every 10 min within the first hour p.i. and after 3,
5, 8, 24, and 48 hrs p.i. The fluorescence was excited at 696 nm
and emission was measured at 720 nm for 10 s. Using the
autofluorescence measured for all animals before the injection of
MSA, a fluorescence threshold value was determined at 10 counts
per s. Also, regions of interest (ROIs) were drawn around the
injection site of animals treated SC and IM. The maximal
fluorescence measured at the neck (corresponding to SC injection
site) and the right hind leg (corresponding to IM injection site) of
mice administered IP and IV, was used to set the fluorescence
threshold for these ROIs ($70 counts per s).
After 48 hours all mice were euthanized and following organs
and tissues were collected for ex vivo analysis of fluorescence:
bladder, spleen, kidneys, liver, lungs, heart, skin (from site of
injection of animals injected SC and IM), muscle (IM) and plasma.
Organs were stored at 280uC and plasma at 220uC prior to ex
vivo analysis.
Ex vivo fluorescence of spleens, livers and lungs, was measured
on an infra-red imager (Odyssey, LiCore, Germany). The
distribution of MSA-Alexa700 conjugates in all collected organs
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and tissues was determined using an adopted method for the
measurement of anti tumor nanobody biodistribution described by
Oliveira et al [19]. Briefly, organs were first weighed and
homogenized in a radioimmunoprecipitation buffer (RIPA,
50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxy-
cholate and 1% Triton X 100) supplemented with protease
inhibitors (Sigma, the Netherlands). Homogenized solutions were
transferred onto 96-well plates (Greiner bio one, The Netherlands)
and fluorescence was measured on the infra-red imager. The
concentration of MSA-Alexa700 in every organ was calculated
from a standard curve created by serial, two-fold dilutions of
known concentrations of unstressed or stressed MSA-Alexa700
conjugates in RIPA buffer.
Experiment 2: Detailed biodistribution of unstressed and
stressed MSA upon IP administration. Mice (n= 5 per
group) were injected IP with either unstressed or stressed MSA-
Alexa700. Before and after the injection the syringes were
weighted to precisely determine the injected dose of MSA-
Alexa700 conjugates. In vivo fluorescence was assessed before
injection, directly p.i. and before euthanasia (15 min, 1, 3, 8 and
24 hrs p.i) using the BioSpace Photon ImagerTM. Mice were
euthanized by decapitation under isoflurane anesthesia. After-
wards, following organs and tissues were collected for ex vivo
analysis: blood, urine, spleen, liver, kidney (left), stomach, small
and large intestine, urinary bladder, muscle and skin (from right
hind leg), lung, thymus, heart and brain.
Ex vivo fluorescence measurements and analysis of homogenized
tissues and organs was performed as described above.
3. Statistical analysis
All data were first assessed for the normal distribution using the
Shapiro-Wilk test. Because data from the first experiment 1 was
not normally distributed, a Mann-Whitney non-parametric test
was used to assess differences between in vivo fluorescence of the
skin and muscle areas (ROIs) of animals injected IM and SC with
either stressed or unstressed MSA-Alexa700. The same test was
also used to analyze the difference in ex vivo MSA-Alexa700 signal
between the different organs collected from mice treated with
either stressed or unstressed MSA-Alexa700. To compare the
difference in ex vivo MSA-Alexa700 signal between the organs
collected using different injection routes a Kruskal-Wallis test was
employed.
Data obtained during the experiment 2 was also not normally
distributed, therefore also here non-parametric tests were used for
analysis. A Mann-Whitney test was used to assess the difference in
overall fluorescent signal (cumulated for all time points) between
organs from animals injected with either stressed or unstressed
MSA-Alexa700. A Kolmogorov-Smirnov test was employed to
check if the distribution of the fluorescence measured in different
organs ex vivo differed over time between stressed and unstressed
MSA treatment.
Results
1. Characterization of unstressed and stressed MSA
Visual inspection. Stressing the MSA-Alexa700 formulation
via metal catalyzed oxidation resulted in the formation of
insoluble, rapidly sedimending aggregates that were easily
detectible by eye (Figure 1A).
Size exclusion chromatography. Before SEC analysis both
stressed and unstressed MSA-Alexa700 solutions were filtered
through a 0.45 mm nylon filter. Inspection of the filter revealed
that a significant amount of MSA-Alexa700 aggregates was
retained on the filter used for the stressed solution (Figure 1C).
This observation was confirmed by the total AUC of stressed
MSA-Alexa700, which showed a protein loss of ,60% after
filtration when compared with total AUC of unstressed MSA-
Alexa700 (Figure 1F). SEC analysis revealed a reduced percentage
of protein monomers in the stressed MSA-Alexa700 sample when
compared to the unstressed MSA-Alexa700 formulation (76%
unstressed vs 44% stressed formulation). The percentage of protein
dimers was similar in both formulations (8.8% and 10.7%), but the
percentage of trimers and higher molecular weight species was
slightly increased in the stressed MSA-Alexa700 solution (7.9% vs
2.3%). Interestingly, SEC analysis revealed degradation of MSA-
Alexa700 during the stress procedure since the amount of protein
fragments in the stressed formulation was three fold higher
compared to the unstressed formulation (30% vs 10%, respective-
ly).
SEC analysis also allowed estimating the contents of free dye in
the stressed and unstressed MSA-Alexa700 solutions. As shown in
Figure 1F only 2.4% of the fluorescent signal originated from
unbound dye in the unstressed formulation. In contrast, in the
stressed MSA-Alexa700 the contents of free dye seemed to be
higher (8.8%), however after correcting for the protein loss during
filtration of this stressed solution the amount of free dye was
estimated to be 3%.
Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS-PAGE). Silver staining revealed the
presence of multiple multimeric entities (up to the estimated
weight of MSA tetramers) in the unstressed MSA-Alexa700
formulation. However, in this unstressed formulation monomers
were the most abundant species (Figure 1E). Also, no aggregates or
fragments were detected (Figure 1D). In contrast, the stressed
formulation contained significant amounts of both MSA fragments
and aggregates (Figure 1D). In fact, the stressed MSA-Alexa700
contained aggregates, which were too big to enter the gel
(Figure 1E).
DLS and NTA. Both DLS and NTA analyses confirmed that
the stressed MSA-Alexa700 formulation contained higher amount
of aggregates compared to the unstressed formulation (Figure 1F).
For the stressed MSA-Alexa700 DLS analysis revealed presence of
particles with an average size of 2908698 nm and a PDI of
0.48560.083. For the unstressed formulation DLS analysis gave
inconclusive results as the measured size varied from about
400 nm to 20.000 nm depending on the measurement, and the
PDI values were very high (0.7 to 1). NTA measurements showed
the presence of particles in both stressed and unstressed
formulations with an average size of 257651 nm (stressed) and
131627 nm (unstressed). Moreover, NTA analysis showed an
,18 fold increase in particle count in the stressed MSA-Alexa700
solution compared to the unstressed one.
2. In vivo studies
Experiment 1: Biodistribution of unstressed and stressed
MSA upon injection via different routes. In vivo and ex vivo
analysis of MSA-Alexa700 conjugates upon injection revealed
significant differences in biodistribution between the stressed and
non-stressed formulations.
Intravenous injection. As shown in Figure 2 IV injection led
to a rapid distribution of MSA-Alexa700 conjugates throughout
the body in case of both, stressed and unstressed, formulations. At
10 minutes p.i. accumulation of the fluorescent signal was
observed in the area of the liver and 20 min p.i. high fluorescence
was seen in the area of the bladder. At 24 hrs p.i., mice injected
with stressed MSA-Alexa700 displayed fluorescence only in the
liver and bladder areas. In contrast, animals injected with
unstressed MSA-Alexa700 displayed fluorescence at this time
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point in other parts of their bodies as well. Both in vivo and ex vivo
analyses showed that IV injection resulted in similar accumulation
of fluorescent signal in the livers of mice receiving either stressed or
unstressed MSA-Alexa700. Moreover, IV administration resulted
in the highest amount of fluorescence in the liver area of all
injection routes studied in this experiment (p,0.001 for IV vs IP/
IM/SC). The accumulation of MSA-Alexa700 48 hrs p.i. in other
organs than the liver was negligibly low.
An interesting observation made during ex vivo measurements
was the presence of ‘‘hotspots’’ with very high fluorescence in the
lungs and spleens of mice treated with stressed MSA-Alexa700
(Figure 3). Organs collected from animals receiving the unstressed
formulation did not show these ‘‘hotspots’’.
Intramuscular injection. After IM injection, fluorescence
could be measured at the site of injection until the end of the
experiment (Figure 2). Moreover, the intensity of fluorescence
measured in vivo at the site of injection 48 hrs p.i. seemed to be
similar for mice treated with either stressed or unstressed MSA-
Alexa700. However, ex vivo analysis revealed that mice treated with
stressed MSA-Alexa700 displayed higher fluorescence signal in the
muscle compared to mice treated with the unstressed formulation
(p = 0.016). Also clear differences in the distribution kinetics at the
site of injection were observed. Unstressed MSA-Alexa700 seemed
to diffuse or be removed from the injection spot much faster than
the stressed formulation. The spread of fluorescence signal
(increase of ROIs) around the injection spot in animals receiving
unstressed MSA-Alexa700 seemed to be faster and the surface
area of ROIs was significantly higher compared to that of mice
receiving the stressed formulation (p = 0.001). At 3 hrs p.i.
fluorescence was found to be spread throughout the body, for
both stressed and unstressed formulations. This body-wide
fluorescence signal was still measurable 8 hrs p.i. Ex vivo analysis
revealed low accumulation of fluorescent signal of stressed and
unstressed MSA-Alexa700 in the liver 48 hrs p.i..
Intraperitoneal injection. Directly after IP injection of
either stressed or unstressed MSA-Alexa700 conjugates a fluores-
cent signal was detectible in the whole peritoneum (Figure 2). No
significant changes in the fluorescent signal (i.e. intensity or
distribution) were observed within the first hour p.i.. At 3 hours
p.i. fluorescence was detected throughout the body for both
stressed and unstressed MSA-Alexa700 treatments, with a
particular strong signal in the area of the liver and in the bladder.
Up to 8 hrs p.i. fluorescence was detected throughout the body.
24 hours p.i. of stressed and unstressed MSA-Alexa700 a weak
fluorescent signal could still be detected in the area of peritoneum
and liver. However, this signal seemed to be more pronounced in
animals receiving the unstressed formulation. At the end of
experiment (48 hrs p.i.) residual fluorescence could be measured
only in the liver area of mice receiving unstressed MSA-Alexa700.
In contrast, mice injected with stressed MSA-Alexa700 displayed
residual fluorescence in the area of liver and peritoneum.
Ex vivo analysis showed highest fluorescence signal in the isolated
livers (Figures 3), with similar intensity in mice treated with
stressed and unstressed formulations. However, in livers and
spleens isolated from the mice injected with stressed MSA-
Alexa700 ‘‘hotspots’’ of high fluorescence were detected. In
contrast, in mice treated with unstressed MSA-Alexa700 no
‘‘hotspots’’ were observed in either the liver or the spleen and the
fluorescent signal was equally distributed throughout those organs
(Figure 4). Moreover, the total fluorescence signal in spleens
isolated from mice treated with stressed MSA-Alexa700 was
higher than the signal from mice treated with the unstressed
formulation (p = 0.001).
Figure 1. Physicochemical characterization of stressed and unstressed MSA. A) Photography of stressed and unstressed MSA-Alexa700
formulations. B) Fluorescence of unstressed (US) and stressed (S) MSA-Alexa700 formulations measured using an in vivo imager. C) Photography of
0.45 mm nylon filters surface after filtration of MSA-Alexa700 formulation prior to SEC analysis. D) Silver stained results of SDS-page analysis of the
stressed and unstressed MSA-Alexa700 conjugates under non-reducing conditions. Samples order: marker, 0.5 mg and 1 mg of unstressed MSA-
Alexa700, 0.5 mg and 1 mg of stressed MSA-Alexa700. E) Fluorescent analysis of protein separated on the SDS-page gel. Samples order: 0.5 mg and
1 mg of unstressed MSA-Alexa700, 0.5 mg and 1 mg of stressed MSA-Alexa700. The stressed formulation contains aggregates too big to enter the gel
and stuck in the wells (yellow rectangles). F) Summarized results of DLS, NTA and SEC analysis of both stressed and unstressed MSA formulations.
doi:10.1371/journal.pone.0085281.g001
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Figure 2. In vivo determination of distribution of unstressed and stressed MSA-Alexa700 upon injection via different routes. A) In
vivo distribution of fluorescence signal from MSA-Alexa700 conjugates upon injection via IV, IM, IP and SC route in time. B) Change of size of ROIs
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Subcutaneous injection. SC injections resulted in similar to
IM injections distribution pattern of fluorescent signal . After SC
injection, the spread of fluorescent signal from the injection site
seemed to be faster in mice treated with unstressed than with
stressed MSA-Alexa700. However, in contrast to the IM route of
injection, a clear difference in the intensity of fluorescence at the
site of injection between stressed and unstressed formulations was
still visible 48 hrs p.i.. Ex vivo analysis confirmed a significantly
higher amount of MSA-Alexa700 at the site of injection (skin) of
animals receiving the stressed formulation (p= 0.045).
Experiment 2: Detailed biodistribution of unstressed and
stressed MSA upon IP administration. To determine the
biodistribution over time after IP administration animals were
treated with stressed or unstressed MSA-Alexa700 conjugates and
euthanized at designated time points p.i.. Selected organs and
tissues were collected for the ex vivo analysis. The in vivo and ex vivo
measurements showed that some animals were injected incorrectly
as shortly after the injection the fluorescent signal was not equally
distributed throughout the peritoneum and post mortem analysis
revealed presence of injection solution in the intestines or stomach
of these mice. These mice were therefore excluded from the
analysis.
In vivo fluorescence measured up to 24 hrs p.i. was found to be
similar to the previous experiment (data not shown). Description of
results is therefore limited to ex vivo analysis of the fluorescence. As
shown in Figure 5, the ex vivo analysis revealed similar fluorescent
signal (i.e. intensity over time) in the plasma, urine, kidneys,
thymus, small intestine and skin isolated at different time points for
mice injected with either stressed or unstressed MSA-Alexa700.
However, for the spleen, urinary bladder, liver, heart, lungs, large
intestine, brain, muscle and stomach significant differences in
distribution of fluorescent signal over time were found. Similar to
the first experiment, the highest fluorescent signal was found in the
liver at 3 hrs p.i., and this signal was almost 6 times higher in mice
treated with the unstressed formulation compared to animals
injected with stressed MSA-Alexa700 (1091.46154.6% ID/g
tissue and 209.7655.8 ID/g tissue, respectively). Accordingly,
the distribution over time (p = 0.001) and magnitude of fluorescent
signal (p = 0.004) differed in the livers of mice injected with
unstressed and stressed MSA-Alexa700.
Although no significant difference was found between the
overall fluorescence signals of spleens of mice treated with stressed
or unstressed MSA-Alexa700, the distribution of fluorescent signal
over time differed between these groups (p = 0.041). Within the
first 8 hrs p.i. a higher fluorescent signal was present in the spleens
of mice receiving unstressed MSA-Alexa700 compared to mice
that received the stressed formulation. At 3 hrs p.i., the
fluorescence measured in the spleens of mice injected with
unstressed MSA-Alexa700 was 3 times higher than the fluores-
cence of spleens from animals treated with stressed MSA-
Alexa700. However, at 24 hrs p.i. the fluorescence measured in
the spleens of mice injected with stressed MSA-Alexa700 was
found to be 3 times higher than in spleens of mice injected with
unstressed MSA-Alexa700. Moreover, in mice treated with
drawn around the injection site of animals injected IM or SC. The black line shows results obtained in animals injected with unstressed MSA-Alexa700
and red from animals treated with stressed protein.
doi:10.1371/journal.pone.0085281.g002
Figure 3. Ex vivo determination of distribution of unstressed and stressed MSA-Alexa700 48 hrs post injection. Distribution of
fluorescence signal in different organs 48 p.i. via IV, IM, IP and SC routes. The bars show average accumulation of MSA-Alexa700 conjugates6 SD. The
black bars show results obtained from animals injected with stressed protein and white bars indicate unstressed protein.
doi:10.1371/journal.pone.0085281.g003
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stressed MSA-Alexa700 again ‘‘hotspots’’ with high fluorescence
signal were present (like observed in the first experiment).
While in most of organs the fluorescence was increasing until
3 hrs p.i., the signal in the intestines of mice injected with stressed
MSA-Alexa700has already reached a maximum 15 min p.i..
Interestingly, the fluorescence in the large intestines of mice
treated with both stressed and unstressed MSA-Alexa700 was
much higher than in the small intestines.
Discussion
Presence of protein aggregates in the formulation of therapeutic
proteins has been identified as a major risk factor for immuno-
genicity. However, there is almost no data showing the fate of
these aggregates upon injection. It has been hypothesized that
aggregates can persist at the site of injection, especially when
applied SC or IM, much longer than protein monomers.
Therefore aggregates may trigger the activation of immune cells
located at the site of injection more efficiently than monomers.
Current experiments were designed to study the biodistribution
of unstressed, mainly monomeric, and stressed, mostly aggregated,
MSA in mice when applied via different routes. We first showed
that metal catalyzed oxidation is an effective way to obtain a MSA
formulation containing high amounts of aggregates. Subsequently,
we showed that stressed MSA-Alexa700 persists longer at the site
of injection compared to unstressed MSA-Alexa700 after SC and
IM administration. The time frame, in which the experiment was
performed (up to 48 hrs), did not allow for a complete clearance of
fluorescence at the injection site, however it could be hypothesized
that in a longer experiment these differences between stressed and
unstressed MSA Alexa700 treatment would be further magnified.
Nonetheless, our observation that stressed MSA-Alexa700 persists
longer at the site of injection is in agreement with the hypothesis
that aggregates are cleared slower than monomers when given SC.
This might explain why for some drugs SC route appears to be the
most immunogenic.
High immunogenicity of proteins when injected IV has been
described for rhIFNb [11], PEGylated Factor VIII [12] and
antiTNFa antibody [20]. In our previous manuscript we suggested
that aggregates, when injected directly into the blood stream,
might be rapidly removed by the macrophages of the reticuloen-
dothelial system in the spleen, in a similar manner as in case of
liposomes exceeding 100 nm in diameter [18]. In current
experiment we induced the formation of aggregates exceeding
100 nm and small, highly fluorescent ‘‘hotspots’’ in the spleens
were present. These spots might be aggregates caught by
macrophages or might be aggregates that are stuck in the blood
vessels. Considering these spots in the spleen and potential
importance of macrophage uptake it would be worth performing
an in depth study on what causes these ‘‘hotspots’’, not only for IV
administration, but for IP treatment as well.
Another very interesting finding was that ‘‘hotspots’’ were also
found in the lungs of mice treated IV with stressed MSA-
Alexa700. Since the lungs are composed of very small blood
capillaries it appears likely that aggregates might have clogged
them. It is possible that macrophages present in the lung tissue
take up these particles and therefore increase immunogenicity.
The biodistribution of MSA-Alexa700 upon IP administration
differs depending on the amount of aggregates in the formulation.
In general, the accumulation of fluorescently labeled and stressed
MSA seems lower in the majority of organs compared to
accumulation of unstressed MSA. This could be due to a lower
diffusion rate of the stressed protein through the peritoneum as
well as due to a slower uptake of aggregates by the lymphatic
transportation system. A very interesting observation was the
longer persistence of fluorescent signal and its inhomogeneous
distribution (hotspots) in the spleens of animals injected with
stressed MSA-Alexa700. The mechanism, by which these hotspots
are formed, is not clear. Their size and number suggests that the
origin of ‘‘hotpots’’ in spleens from mice injected IP differs from
those found in mice administered IV. IV injection with MSA-
Alexa700 induced a high number of small ‘‘hotspots’’, while IP
administration resulted in a low number of ‘‘hotspots’’ with a
relatively large surface. Further studies, on what composes these
‘‘hotspots’’ and how they are formed, are therefore needed.
Although the data presented in this manuscript seems to explain
some observations described in the literature on how the route of
administration affects immunogenicity of protein drugs, one
should be aware of the limitations of the employed assays and
mouse model. Because we aimed at obtaining an autologous
system we have chosen MSA as a protein model. However, as
MSA receptors are located in liver and the liver being the main
organ of MSA metabolism [21,22], the elevated fluorescence
signal in this organ might not be representative for other proteins.
Moreover, choosing a self-protein as a model did not allow direct
detection of injected protein by ELISA for example, because of
high background signal from endogenous MSA. Therefore the
detection of injected MSA could only be done with the use of a
label, in this case Alexa-700. A possible issue that could arise is the
dye separating from the protein during the degradation of MSA-
Alexa700 conjugates in liver, resulting in the detection of free dye
and not of the protein itself. We showed that our injected MSA
formulations contained less than 5% of free dye, which should not
interfere with the detection of the conjugated MSA-Alexa700.
However, our data also suggests that MSA-Alexa700 might be
degraded quite rapidly in vivo (within hours). Because the MSA-
Alexa700 conjugates are too big to be filtered out by kidneys, the
fluorescence found in the urine most likely originates from MSA-
Alexa700 degradation. The fluorescent signal in the urine was
high (reaching at maximum almost 3000% of ID/ml), which
Figure 4. Stressed MSA-Alexa700 formed fluorescent ‘‘hot-
spots’’ in lungs, livers and spleens of mice injected IP and IV. A)
IV injection of stressed MSA-Alexa700 resulted in the formation of
fluorescent ‘‘hotspots’’ in the lungs and spleens. B) In livers and spleens
of animals IP injected with stressed protein clumps of highly fluorescent
signal were observed.
doi:10.1371/journal.pone.0085281.g004
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therefore supports degradation of MSA-Alexa700 conjugates and
suggests that the degradation product might differ in spectral
properties from conjugates. Release of free dye might potentially
lead to an overestimation of MSA-Alexa700 concentration in
collected organs and tissues. However, any free dye released by
MSA-Alexa700 catabolism in liver would be most probably
rapidly removed from the circulation by renal filtration due to the
small size of Alexa700. Our data seem to confirm this hypothesis.
Moreover, additional SDS-PAGE analysis of selected samples of
the livers, spleens, lungs and skin suggested degradation of MSA-
Alexa700 in livers but not in other organs (see Appendix S1 and
Figure S1). Very high fluorescence was found only in the liver,
urinary bladder and urine. Moreover, relatively low signal in
plasma suggests rapid removal of free dye from the circulation and
therefore low background signal potentially originating from free
dye. Thus, any accumulation of fluorescent signal in organs other
than liver or urinary bladder is most likely a result of MSA-
Alexa700 conjugates present in those organs and not due to the
fluorescence of free dye from blood. Moreover, lower fluorescent
signal in almost all organs/tissues collected from mice injected IP
with stressed MSA-Alexa700 strongly suggests slower and/or less
efficient diffusion/lymphatic uptake of the stressed formulation
through the peritoneum into the blood circulation. Nevertheless,
the most crucial findings described in this manuscript, i.e. i) longer
retention of stressed (aggregated) than unstressed MSA-Alexa700
at the site of injection after SC and IM administration, ii)
formation of fluorescence ‘‘hotspots’’ in lungs, liver and spleen of
mice injected IV or IP with the stressed formulation, iii) lower
accumulation of the fluorescent signal in most organs after IP
injection of stressed MSA rather than unstressed MSA-Alexa700,
can only be explained by differences in biodistribution between
stressed and unstressed MSA-Alexa700.
Figure 5. Detailed biodistribution over time of unstressed and stressed MSA-Alexa700 upon IP injection. The biodistribution of the
MSA-Alexa700 over time in animals IP injected with stressed (red line) and unstressed (black line) formulations. The accumulation of fluorescent signal
is expressed as percent of injected dose per gram of tissue (% ID/g tissue) or percent of injected dose per ml of plasma or urine (% ID/ml).
doi:10.1371/journal.pone.0085281.g005
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Conclusions
In this report we show that in vivo florescence imaging, despite
some drawbacks, is a valuable method to study the biodistribution
of protein (aggregates) upon injection. We showed (i) that
biodistribution of MSA differs depending on the formulation
(stressed or unstressed) and (ii) that the biodistribution of MSA
strongly depends on the application route. Furthermore, IV and IP
injections of stressed MSA-Alexa700 resulted in the formation of
fluorescent ‘‘hotspots’’ in spleens (IP and IV), livers (IP) and lungs
(IV), suggesting entrapment of MSA-Alexa700 aggregates in the
microenvironment that might enhance induction of antibody
responses.
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Appendix S1 Testing of potential in vivo degradation of
MSA-Alexa700 conjugates. Methodology and results.
(DOCX)
Figure S1 SDS-PAGE analysis of samples collected in in
vivo experiments 1 (A–C) and 2 (D). A) Skin samples
collected from mice injected SC, B) lungs’ samples from mice
injected IV, C) Spleen samples from mice injected IP. D) Liver
samples collected at different time points in the Study 2.4. US -
unstressed MSA-Alexa700, S - stressed MSA-Alexa700. D/ml).
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